<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">MONOCTANOIN</span><br/>(mon-oh-ock'ta-noyn)<br/><span class="topboxtradename">Moctanin<br/></span><b>Classifications:</b> <span class="classification">gastrointestinal agent</span>; <span class="classification">cholelitholytic</span><br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>120 mL infusion</p>
<h1><a name="action">Actions</a></h1>
<p>Cholesterol solubilizing agent that shrinks, softens, and dissolves cholesterol gallstones, depending on size and number.
         An effective alternative to gallstones removal in some patients, superior to other solvent-type medications (e.g., chenodiol).
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Clinical efficacy related mainly to amount of cholesterol in the stones. Complete dissolution is more likely when there is
         only one stone than when multiple stones are present.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>To dissolve cholesterol (radiolucent) gallstones retained in the biliary tract after cholecystectomy when other means are
         not viable or are unsuccessful.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Noncholesterol gallstones; impaired liver function; obstructive jaundice; pancreatitis; history of intolerance of vegetable
         oils; recent duodenal ulcer, or jejunitis, infection. Safety during pregnancy (category C) or in children <img src="../images/special/lesserorequal.gif"/>2
         y is not established.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Bile duct obstruction; lactation.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Radiolucent Gallstones</span><br/><span class="rdage">Adult:</span> <span class="rdroute">Biliary Instillation</span> 35 mL/h at pressure of 10 cm H<sub>2</sub>O for 210 d (avg: 5 d)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Instillation</span><br/><ul>
<li>Give by continuous perfusion through a percutaneous transhepatic catheter directly inserted into the common bile duct.</li>
<li>Administer (usually) with a positive pressure or peristaltic perfusion pump equipped with an over-flow manometer. Monitor
            pressure to prevent exceeding 15 cm H<sub>2</sub>O.
         </li>
<li>Monitor flow rate carefully and adjust if necessary. If rate is too fast, incidence of GI adverse effects are apt to increase.
            Be alert to persistent nausea and diarrhea.
         </li>
<li>
            				Note: Perfusion temperature is brought to room temperature [21°27° C (70°80° F)] before the perfusion
            is started.
            			
         </li>
<li>Interrupt perfusion for 12 h at mealtimes to reduce GI adverse effects.</li>
<li>Store at 15°30° C (59°86° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Drowsiness, depression. <span class="typehead">GI:</span>
<span class="speceff-common">Abdominal pain,</span> epigastric burning, anorexia, <span class="speceff-common">nausea, vomiting, diarrhea,</span> reversible irritability of duodenal mucosa, pancreatitis (rare). <span class="typehead">Hematologic:</span> Bleeding from duodenal ulcer, hypokalemia, increase in serum amylase. <span class="typehead">Body as a Whole:</span> Shortness of breath, pruritus, fatigue, diaphoresis, fever, facial flushing. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> No clinically significant interactions established. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Metabolism:</span> Metabolized by pancreatic lipase and other digestive enzymes to fatty acids and glycerol, which are readily absorbed by the
      portal vein. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Relieve discomfort from adverse effects by temporary interruption of the treatment. Abdominal pain does not appear to be dose-
            or perfusion-rate dependent. If adverse effects persist, drug may be discontinued.
         </li>
<li>Monitor vital signs. An elevated temperature with chills combined with severe right upper quadrant abdominal pain and jaundice
            suggest onset of ascending cholangitis. Report to physician.
         </li>
<li>Correlate lab studies of WBC with patient's complaint of sore throat accompanied by fever and chills; rule out leukopenia.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>